Immunome Inc. (IMNM): who owns it and who trades it
As of Nov 16, 2026, IMNM insiders reported 28 open-market sales worth $27.5M and 11 purchases worth $2.3M in the last 12 months, with 94% of the sale value made under pre-set 10b5-1 plans. The largest seller was Isaac Barchas (Director), with $18.3M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Immunome
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMNM
203 funds and institutions reported IMNM shares worth $2.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Investment Management, Inc. with 17.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19.68M | 17.39% | $417M | +20% |
| FMR LLC (Fidelity) | 16.99M | 15.02% | $360M | +0% |
| BlackRock, Inc. | 8.81M | 7.78% | $187M | +8% |
| State Street Corp | 5.49M | 4.86% | $116M | +2% |
| Wellington Management Group LLP | 5.21M | 4.61% | $110M | +10% |
| Redmile Group, LLC | 4.91M | 4.34% | $104M | -12% |
| Primecap Management Co | 4.58M | 4.05% | $97.1M | -4% |
| Vanguard Capital Management LLC | 4.55M | 4.02% | $96.4M | +3% |
| Driehaus Capital Management LLC | 4.35M | 3.84% | $92.1M | +6% |
| Enavate Sciences Gp, LLC | 3.61M | 3.19% | $76.6M | No change |
| Geode Capital Management, LLC | 2.75M | 2.44% | $58.4M | +8% |
| Morgan Stanley | 2.41M | 2.13% | $51M | -15% |
| California State Teachers Retirement System | 2.29M | 2.03% | $108M | +1958% |
| Silverarc Capital Management, LLC | 2.02M | 1.78% | $42.7M | +9% |
| JPMorgan Chase & Co | 1.85M | 1.63% | $39M | – |
| T. Rowe Price Associates | 1.77M | 1.57% | $37.6M | -38% |
| Sofinnova Investments, Inc. | 1.72M | 1.52% | $36.5M | +1% |
| Readystate Asset Management LP | 1.61M | 1.42% | $34M | +23% |
| Goldman Sachs Group Inc | 1.51M | 1.34% | $32M | +37% |
| Vanguard Portfolio Management LLC | 1.35M | 1.19% | $28.6M | +34% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMNM insiders reported $2.3M of open-market purchases and $27.5M of sales. 94% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Jack Higgins | Chief Scientific Officer | Sale plan | 13,200 | $25.32 | $334K | Form 4 |
| Aug 12, 2026 | Isaac Barchas | Director | Sale plan | 11,048 | $27.25 | $301K | Form 4 |
| Aug 11, 2026 | Isaac Barchas | Director | Sale plan | 62,291 | $26.23 | $1.6M | Form 4 |
| Aug 10, 2026 | Isaac Barchas | Director | Sale plan | 10,125 | $26.07 | $264K | Form 4 |
| Aug 7, 2026 | Isaac Barchas | Director | Sale plan | 15,248 | $26.06 | $397K | Form 4 |
| Aug 6, 2026 | Isaac Barchas | Director | Sale plan | 20,840 | $26.06 | $543K | Form 4 |
| Aug 4, 2026 | Kinney Horn | CHIEF BUSINESS OFFICER | Sale plan | 90,616 | $25.09 | $2.3M | Form 4 |
| Jul 7, 2026 | Kinney Horn | CHIEF BUSINESS OFFICER | Sale plan | 1,092 | $25.00 | $27.3K | Form 4 |
| Jul 7, 2026 | Isaac Barchas | Director | Sale plan | 16,906 | $24.20 | $409K | Form 4 |
| Jul 6, 2026 | Isaac Barchas | Director | Sale plan | 83,094 | $24.11 | $2M | Form 4 |
| Jul 2, 2026 | Robert Lechleider | Chief Medical Officer | Sale plan | 16,072 | $23.44 | $377K | Form 4 |
| Jul 2, 2026 | Robert Lechleider | Chief Medical Officer | Sale plan | 16,214 | $22.76 | $369K | Form 4 |
| Jul 2, 2026 | Robert Lechleider | Chief Medical Officer | Sale plan | 22,714 | $21.95 | $499K | Form 4 |
| Jul 2, 2026 | Isaac Barchas | Director | Sale plan | 75,665 | $22.35 | $1.7M | Form 4 |
| Jul 2, 2026 | Isaac Barchas | Director | Sale plan | 24,335 | $23.33 | $568K | Form 4 |
| Jun 30, 2026 | Isaac Barchas | Director | Sale plan | 101,050 | $21.12 | $2.1M | Form 4 |
| Jun 25, 2026 | Robert Lechleider | Chief Medical Officer | Sale plan | 40,580 | $19.56 | $794K | Form 4 |
| Jun 25, 2026 | Robert Lechleider | Chief Medical Officer | Sale plan | 14,420 | $20.66 | $298K | Form 4 |
| Jun 15, 2026 | Max Rosett | CFO | Sale plan | 60,000 | $18.23 | $1.1M | Form 4 |
| Jun 5, 2026 | Jean Jacques Bienaime | Director | Sale | 500 | $19.44 | $9.7K | Form 4 |
| Jun 5, 2026 | Jean Jacques Bienaime | Director | Sale | 10,000 | $19.41 | $194K | Form 4 |
| Jun 5, 2026 | Jean Jacques Bienaime | Director | Purchase | 6,000 | $19.48 | $117K | Form 4 |
| Jun 5, 2026 | Jean Jacques Bienaime | Director | Purchase | 3,500 | $19.46 | $68.1K | Form 4 |
| Jun 5, 2026 | Jean Jacques Bienaime | Director | Purchase | 1,000 | $19.27 | $19.3K | Form 4 |
| May 15, 2026 | Jean Jacques Bienaime | Director | Purchase | 5,000 | $20.70 | $104K | Form 4 |
| Apr 2, 2026 | Jack Higgins | Chief Scientific Officer | Sale plan | 9,438 | $21.64 | $204K | Form 4 |
| Apr 2, 2026 | Max Rosett | CFO | Sale plan | 1,344 | $22.48 | $30.2K | Form 4 |
| Apr 2, 2026 | Max Rosett | CFO | Sale plan | 63,656 | $21.91 | $1.4M | Form 4 |
| Mar 27, 2026 | Clay B Siegall | CEO | Purchase | 25,450 | $19.67 | $501K | Form 4 |
| Mar 23, 2026 | Philip Wagenheim | Director | Sale | 28,200 | $20.65 | $582K | Form 4 |
| Mar 20, 2026 | Philip Wagenheim | Director | Sale | 36,800 | $20.47 | $753K | Form 4 |
| Mar 11, 2026 | Jean Jacques Bienaime | Director | Purchase | 1,000 | $21.55 | $21.6K | Form 4 |
| Mar 10, 2026 | Jean Jacques Bienaime | Director | Purchase | 1,000 | $22.12 | $22.1K | Form 4 |
| Dec 30, 2025 | Clay B Siegall | CEO | Purchase | 4,729 | $21.15 | $100K | Form 4 |
| Dec 22, 2025 | Isaac Barchas | Director | Sale plan | 371,949 | $21.72 | $8.1M | Form 4 |
| Dec 22, 2025 | Isaac Barchas | Director | Sale plan | 11,251 | $22.34 | $251K | Form 4 |
| Dec 19, 2025 | Clay B Siegall | CEO | Purchase | 7,278 | $20.48 | $149K | Form 4 |
| Dec 19, 2025 | Philip Tsai | Chief Technical Officer | Purchase | 10,000 | $20.49 | $205K | Form 4 |
| Dec 18, 2025 | Clay B Siegall | CEO | Purchase | 46,511 | $21.50 | $1000K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Isaac Barchas | Director | – | $18.3M | Aug 12, 2026 |
| Max Rosett | Chief Financial Officer | – | $2.5M | Jun 15, 2026 |
| Robert Lechleider | Chief Medical Officer | – | $2.3M | Jul 2, 2026 |
| Kinney Horn | CHIEF BUSINESS OFFICER | – | $2.3M | Aug 4, 2026 |
| Clay B Siegall | President and CEO, Director | $1.7M | – | Mar 27, 2026 |
| Philip Wagenheim | Director | – | $1.3M | Mar 23, 2026 |
| Jean Jacques Bienaime | Director | $351K | $204K | Jun 5, 2026 |
| Jack Higgins | Chief Scientific Officer | – | $538K | Sep 11, 2026 |
| Philip Tsai | Chief Technical Officer | $205K | – | Dec 19, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMNM short interest
High short interest. 14.2% of IMNM shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 8%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 16.17M IMNM shares were sold short, 14.2% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 12.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 16.17M | 14.24% | -6% | 1.27M | 12.8 |
| Oct 15, 2026 | 17.28M | 15.22% | +3% | 1.42M | 12.2 |
| Sep 30, 2026 | 16.76M | 14.75% | +3% | 1.69M | 9.9 |
| Sep 15, 2026 | 16.24M | 14.30% | +4% | 787,598 | 20.6 |
| Aug 31, 2026 | 15.63M | 13.77% | -10% | 1.24M | 12.6 |
| Aug 14, 2026 | 17.39M | 15.31% | -3% | 1.17M | 14.9 |
| Jul 31, 2026 | 17.98M | 15.89% | +4% | 782,638 | 23.0 |
| Jul 15, 2026 | 17.24M | 15.24% | -1% | 1.64M | 10.5 |
| Jun 30, 2026 | 17.37M | 15.35% | -4% | 2.14M | 8.1 |
| Jun 15, 2026 | 18.15M | 16.04% | +8% | 1.40M | 12.9 |
| May 29, 2026 | 16.86M | 14.91% | -4% | 1.19M | 14.2 |
| May 15, 2026 | 17.63M | 15.58% | -6% | 878,987 | 20.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Immunome company events
Immunome filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 5, 2026AgreementImmunome, Inc. entered into Amendment No. 4 to License Agreement with Bristol-Myers Squibb Company to further amend the License Agreement, by and between BMS and the Company (as assignee of Ayala Pharmaceuticals, Inc.), dated as of November 29, 2017 (as amended, the “License Agreement”). Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Dec 17, 2025AnnouncementImmunome, Inc. entered into an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public… Filing
- Dec 15, 2025AnnouncementImmunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Immunome financials
Famous investors that hold IMNM
3 of the 50 well-known investors we track reported holding IMNM in their latest 13F filing. The largest position is Ken Griffin's, worth $10.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 473,537 | $10.2M | 0.0% | +111% |
| Israel Englander · Millennium Management | Q3 2026 | 62,191 | $1.3M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 35,170 | $757K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named IMNM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.3% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.3% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.0% |
Questions about Immunome Inc. (IMNM) stock
Who owns the most IMNM stock?
The largest reported owner of Immunome Inc. (IMNM) is T. Rowe Price Investment Management, Inc., with 17.4% of the company. In total, 203 funds and institutions reported holding IMNM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are IMNM insiders buying or selling?
In the last 12 months, IMNM insiders reported 11 open-market purchases worth $2.3M and 28 sales worth $27.5M. The latest trade was on Sep 11, 2026. See every trade.
What is the short interest in IMNM?
As of Oct 30, 2026, 16.17M IMNM shares were sold short, 14.2% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 12.8 trading days (days to cover). See the history.
Which famous investors hold IMNM?
3 of the 50 well-known investors we track reported IMNM in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $10.2M. See all holders.
Executive pay
Immunome's chief executive was paid a total of $7.7M for the year ended Dec 31, 2025, down 17% from $9.2M the year before. In the last 12 months, Immunome's executives and directors bought $2.3M of stock on the open market and sold $27.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.